Neumann-Raizel Hagit, Shilo Asaf, Lev Shaya, Mogilevsky Maxim, Katz Ben, Shneor David, Shaul Yoav D, Leffler Andreas, Gabizon Alberto, Karni Rotem, Honigman Alik, Binshtok Alexander M
Department of Medical Neurobiology, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University, Jerusalem, Israel.
Front Pharmacol. 2019 Oct 15;10:1198. doi: 10.3389/fphar.2019.01198. eCollection 2019.
Targeted delivery of therapeutic compounds to particular cell types such that they only affect the target cells is of great clinical importance since it can minimize undesired side effects. For example, typical chemotherapeutic treatments used in the treatment of neoplastic disorders are cytotoxic not only to cancer cells but also to most normal cells when exposed to a critical concentration of the compound. As such, many chemotherapeutics exhibit severe side effects, often prohibiting their effective use in the treatment of cancer. Here, we describe a new means for facilitated delivery of a clinically used chemotherapy compound' doxorubicin, into hepatocellular carcinoma cell line (BNL1 ME). We demonstrate that these cells express a large pore, cation non-selective transient receptor potential (TRP) channel V2. We utilized this channel to shuttle doxorubicin into BNL1 ME cells. We show that co-application of either cannabidiol (CBD) or 2-APB, the activators of TRPV2 channels, together with doxorubicin leads to significantly higher accumulation of doxorubicin in BNL1 ME cells than in BNL1 ME cells that were exposed to doxorubicin alone. Moreover, we demonstrate that sub-effective doses of doxorubicin when co-applied with either 2-APB or CBD lead to a significant decrease in the number of living BNL1 ME cell and BNL1 ME cell colonies in comparison to application of doxorubicin alone. Finally, we demonstrate that the doxorubicin-mediated cell death is significantly more potent, requiring an order of magnitude lower dose, when co-applied with CBD than with 2-APB. We suggest that CBD may have a dual effect in promoting doxorubicin-mediated cell death by facilitating the entry of doxorubicin TRPV2 channels and preventing its clearance from the cells by inhibiting P-glycoprotein ATPase transporter. Collectively, these results provide a foundation for the use of large pore cation-non selective channels as "natural" drug delivery systems for targeting specific cell types.
将治疗性化合物靶向递送至特定细胞类型,使其仅影响靶细胞,这在临床上具有重要意义,因为它可以将不良副作用降至最低。例如,用于治疗肿瘤疾病的典型化疗方法具有细胞毒性,当暴露于临界浓度的化合物时,不仅对癌细胞有毒性,而且对大多数正常细胞也有毒性。因此,许多化疗药物会表现出严重的副作用,常常阻碍其在癌症治疗中的有效应用。在此,我们描述了一种促进临床使用的化疗化合物阿霉素递送至肝癌细胞系(BNL1 ME)的新方法。我们证明这些细胞表达一种大孔、阳离子非选择性瞬时受体电位(TRP)通道V2。我们利用该通道将阿霉素转运至BNL1 ME细胞中。我们表明,与单独暴露于阿霉素的BNL1 ME细胞相比,共同应用大麻二酚(CBD)或TRPV2通道激活剂2-APB与阿霉素一起可导致阿霉素在BNL1 ME细胞中的积累显著更高。此外,我们证明,与单独应用阿霉素相比,当亚有效剂量的阿霉素与2-APB或CBD共同应用时,可导致存活的BNL1 ME细胞和BNL1 ME细胞集落数量显著减少。最后,我们证明,与2-APB共同应用时相比,与CBD共同应用时,阿霉素介导的细胞死亡效力显著更强,所需剂量低一个数量级。我们认为,CBD可能通过促进阿霉素进入TRPV2通道并通过抑制P-糖蛋白ATP酶转运体防止其从细胞中清除,在促进阿霉素介导的细胞死亡方面具有双重作用。总体而言,这些结果为将大孔阳离子非选择性通道用作靶向特定细胞类型的“天然”药物递送系统奠定了基础。